BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average […]